A New Vaccine to Protect Against Lyme Disease Begins Final Trial
A vaccine that would protect people as young as 5 years old from Lyme disease is recruiting participants for its third and final clinical trial, according to an announcement by Pfizer and the French pharmaceutical company Valneva, developers of the vaccine.The trial, Vaccine Against Lyme for Outdoor Recreationists (VALOR) will investigate the efficacy, safety, and immunogenicity of the investigational Lyme disease vaccine candidate, VLA15.“We are extremely pleased to reach this important milestone in the development of VLA15. Lyme disease continues to spread, representing a high unmet medical need that impacts the lives of many in the Northern Hemisphere,” said Juan Carlos Jaramillo, MD, chief medical officer of Valneva, in a release. “We look forward to further investigating the VLA15 candidate in phase 3, which will take us a step closer…